Author: MIL OSI Publisher

Question for written answer  E-001592/2025
to the Commission
Rule 144
Sandro Gozi (Renew), Yvan Verougstraete (Renew), Ciaran Mullooly (Renew), Céline Imart (PPE), Joachim Streit (Renew), Christine Singer (Renew), Engin Eroglu (Renew)

Europe’s chemicals industry is lacking in recycled plastics: it has the capacity for 4.6 million tonnes, and will need 12 million tonnes by 2030. Compostable, biobased plastics are an environmentally friendly solution and represent a potential production of 2.8 million tonnes by 2027. They could cut CO₂ emissions by 30-80 % and use European agricultural starch, which would create added value totalling more than EUR 500 million every year.

Delays to the review of biobased plastics by Article 8 of the Packaging and Packaging Waste Directive could hold up these sustainable alternatives and cause a 35 % increase of plastic waste imports into the EU.

Composting standards (EN 13432) need to be urgently revised. Speeding up revision could create 160 000 jobs, add EUR 37 billion to the EU’s GDP by 2030 and increase industrial investment by 45 % in three years.

• 1.Can the Commission speed up the review of biobased plastics by 2028 established by Article 8 of the Packaging and Packaging Waste Regulation?
• 2.Does the Commission intend to review composting standards and develop an industrial strategy for bioplastics?

Submitted: 22.4.2025

Question for written answer  E-001593/2025
to the Commission
Rule 144
Tomislav Sokol (PPE)

Parliament’s Special Committee on Beating Cancer (BECA) report explicitly recognised the importance of nutritional care as an integral component of cancer treatment. However, Europe’s beating cancer plan from the Commission appears to have omitted specific provisions regarding nutritional care for cancer patients.

Disease-related malnutrition is a significant comorbidity affecting patients with cancer, impacting treatment outcomes, quality of life and survival rates. Proper nutritional assessment, monitoring and personalised interventional strategies have been demonstrated to improve treatment tolerance, reduce complications and enhance overall patient outcomes.

In the light of this:

• 1.Does the Commission intend to incorporate comprehensive nutritional care recommendations into the next review of Europe’s beating cancer plan and its implementing activities, in alignment with Parliament’s BECA report findings?
• 2.What specific measures does the Commission envision to ensure proper diagnosis of malnutrition risk among patients with cancer, systematic nutritional monitoring and personalised nutritional interventions for patients in need?
• 3.How does the Commission plan to address the current gap between scientific evidence supporting nutritional care in oncology and its implementation in cancer care pathways across Member States?

Submitted: 22.4.2025

The Commission is committed to citizen participation and engagement as part of its policymaking process. Citizen engagement is underpinned by a robust methodology, based on established criteria.

The participants in the European Citizens’ Panels are selected based on a fully randomised selection process with the aim to compose a group representative of EU diversity.

The following elements are taken into account to ensure diversity: origin from one of the 27 Member States, gender, age (with one third of participants being between 16 and 25 years old), residence in an urban or rural area, level of education, professional activity, and the image held of the EU.

The last element guarantees that the same diversity of views found in Eurobarometer surveys (negative, neutral, or positive image of the EU) is reflected in the Panel. In addition, the panels are keenly observed by a range of experts and interested parties.

For the selection of participants in the Youth Policy Dialogues, the Commission also aims for diversity in the groups. It has made efforts to achieve balance in terms of gender, nationality and geography (including from rural areas and cities), and to mix participants from youth networks and from outside such networks.

Both the Panels and the Dialogues are accessible for people with disabilities.

Question for written answer  E-001594/2025
to the Commission
Rule 144
Tomislav Sokol (PPE)

Immunosenescence, the age-related decline in immune function, increases the vulnerability of older adults to infectious diseases, such as influenza or COVID-19, as well as non-communicable diseases, including cancer. With one third of EU citizens projected to be over 65 by 2100, addressing this challenge becomes even more urgent as immunosenescence reduces both the immune response to infection and the protection provided by influenza vaccination. Despite this, national vaccination strategies often do not fully account for these age-related changes, limiting their impact. With Europe’s ageing demographic, ensuring that vaccination strategies are optimised for older adults is critical for public health and economic sustainability.

In this context:

• 1.What actions will the Commission undertake to encourage the Member States to adapt their national vaccination programmes to better account for immunosenescence, ensuring older adults receive the most effective and appropriate vaccines available?
• 2.How does the Commission plan to work with the European Centre for Disease Prevention and Control to develop more specific guidance on age-related vaccine recommendations, ensuring that national immunisation strategies reflect the latest scientific evidence on vaccine effectiveness in older populations?

Submitted: 22.4.2025

Question for written answer  E-001548/2025
to the Council
Rule 144
Pierre Jouvet (S&D)

Over the past three years, Europe has seen a massive influx of products imported from China via e-commerce platforms that do not comply with European safety standards. Sent directly to consumers, they are exempt from customs controls and are exempt from charges, as their value is less than EUR 150.

The volume of these products doubles each year. A US decree signed on 8 April 2025 provides for a tripling of tariffs on such parcels arriving in the US. This measure could induce China to redirect these export flows to the EU, further increasing the volume of imports.

• 1.What does the EU plan to do to speed up the end of the customs exemption for such imports? Work on the reform of the Customs Union Code is progressing slowly. Will this reform be completed in time to be implemented in 2028, and is the EU prepared to bring this exemption to an end more swiftly?
• 2.What certainty is there that China will honour the commitments it made during Commissioner Šefčovič’s visit to the country?

Submitted: 16.4.2025

Question for written answer  E-001598/2025
to the Commission
Rule 144
Christine Schneider (PPE)

As soon as the amount of tax relief reaches EUR 10 000 for the 2024 calendar year, beneficiaries must submit a multi-page tax declaration. These declarations can be over 60 pages long. The lowering of the reporting threshold to EUR 10 000 per calendar year affects producers who are active in primary agricultural production and in fisheries and aquaculture.

• 1.Why has the Commission lowered the reporting threshold from EUR 100 000 to EUR 10 000?
• 2.Under what conditions can the reporting threshold be raised back to the original EUR 100 000?

Submitted: 22.4.2025